Depression

Overview

Depression has diverse neurobiological substrates including reduced hippocampal neurogenesis, impaired serotonin/norepinephrine signaling, neuroinflammation, and HPA axis dysregulation. Peptide approaches target structural neurobiological deficits rather than symptom management alone. NSI-189 in particular is notable for promoting actual hippocampal neurogenesis — addressing the structural atrophy consistently found in depressed patients.

Recommended Peptides

NSI-189 – synthetic compound stimulating hippocampal neurogenesis; increases hippocampal volume over treatment course; studied in MDD with positive signals; effects accumulate over weeks; often stacked with cognitive peptides given overlapping hippocampal targets
Semax – upregulates BDNF and serotonin; has demonstrated antidepressant effects in addition to its cognitive benefits; intranasal delivery for rapid CNS access
Selank – anxiolytic with antidepressant properties; reduces neuroinflammatory cytokines implicated in treatment-resistant depression; lacks the sedation of conventional antidepressants; Russian-approved for anxiety and depression

Protocols

Cognitive Enhancement Protocol

Related Conditions

Research Summary

Semax (ACTH 4-10 analog) reversed chronic unpredictable stress-induced anhedonia and hippocampal BDNF decreases in rodents (PMID-39442746). BPC-157 modulates both serotonergic and dopaminergic systems (PMID-27138887). Intranasal oxytocin dampens amygdala reactivity in PTSD patients (PMID-26404844). All depression-specific peptide evidence is preclinical or based on small human studies.

#condition #neurological